Green Cross Medical Science Corporation Stock

Equities

A142280

KR7142280007

Medical Equipment, Supplies & Distribution

End-of-day quote Korea S.E. 06:00:00 2024-04-23 pm EDT 5-day change 1st Jan Change
4,085 KRW 0.00% Intraday chart for Green Cross Medical Science Corporation +2.64% -14.36%
Sales 2022 113B 82.12M Sales 2023 94.01B 68.25M Capitalization 101B 73.01M
Net income 2022 -3.58B -2.6M Net income 2023 1.8B 1.3M EV / Sales 2022 1.19 x
Net Debt 2022 12.65B 9.18M Net Debt 2023 16.84B 12.22M EV / Sales 2023 1.25 x
P/E ratio 2022
-34 x
P/E ratio 2023
62.8 x
Employees 131
Yield 2022 *
-
Yield 2023
-
Free-Float 46.71%
More Fundamentals * Assessed data
Dynamic Chart
Green Cross Medical Science Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Green Cross Medical Science Corporation announced that it has received KRW 30 billion in funding from Daishin Securities Co. Ltd., Investment Arm and other investors CI
Green Cross Medical Science Corporation announced that it expects to receive KRW 30 billion in funding from Daishin Securities Co. Ltd., Investment Arm and other investors CI
Oxford Immunotec Global PLC Enters into A Memorandum of Understanding Green Cross Medical Science Corp. to Market the T-SPOT Discovery SARS-CoV-2 Kit, for the Measurement of the T Cell Immune Response to SARS-CoV-2 Infection, in South Korea CI
Hemotune AG announced that it has received CHF 5.1 million in funding from Green Cross Medical Science Corporation, ZKB Start-up Finance, Occident Group AG CI
Green Cross Medical Science Enters into Co-Development Agreement with GeneCast to Develop A New COVID-19 Detection Kit CI
GreenCross Medical Science Corp. cancelled the acquisition of additional 29.54% stake in CERAGEM Medisys, Inc. CI
GreenCross Medical Science Corp. agreed to acquire additional 29.54% stake in CERAGEM Medisys, Inc for KRW 4.6 billion. CI
GreenCross Medical Science Corp. announced that it has received KRW 10 billion in funding from KB Securities Co., Ltd., Investment Arm and other investors CI
GreenCross Medical Science Corp. announced that it has received KRW 10 billion in funding from Kiwoom Securities Co., Ltd., Investment Arm, Korea Investment & Securities Co., Ltd., Investment Arm, Industrial Bank of Korea, Investment Arm, and other investors CI
GreenCross Medical Science Corp. announced that it expects to receive KRW 10 billion in funding from Kiwoom Securities Co., Ltd., Investment Arm, Korea Investment & Securities Co., Ltd., Investment Arm, Industrial Bank of Korea, Investment Arm, and other investors CI
GreenCross Medical Science Corp. announced that it expects to receive funding from KB Securities Co., Ltd., Investment Arm and other investors CI
Tranche Update on GreenCross Medical Science Corp.'s Equity Buyback Plan announced on March 2, 2017. CI
GreenCross Medical Science Corp.'s Equity Buyback announced on March 2, 2017 has closed with 50,000 shares, representing 0.52% for KRW 536.95 million. CI
GreenCross Medical Science Corp. announces an Equity Buyback for 50,000 shares. CI
More news
1 week+2.64%
Current month-7.68%
1 month-9.62%
3 months-9.52%
6 months+13.47%
Current year-14.36%
More quotes
1 week
3 940.00
Extreme 3940
4 125.00
1 month
3 940.00
Extreme 3940
4 585.00
Current year
3 940.00
Extreme 3940
4 960.00
1 year
3 490.00
Extreme 3490
5 880.00
3 years
3 490.00
Extreme 3490
13 350.00
5 years
2 785.00
Extreme 2785
19 950.00
10 years
2 785.00
Extreme 2785
30 800.00
More quotes
Managers TitleAgeSince
Director/Board Member 59 -
Comptroller/Controller/Auditor 70 -
Members of the board TitleAgeSince
Director/Board Member 61 19-03-26
Director/Board Member 59 -
More insiders
Date Price Change Volume
24-04-24 4,085 0.00% 14,882
24-04-23 4,085 -0.73% 10,378
24-04-22 4,115 +3.00% 28,108
24-04-19 3,995 -0.62% 23,967
24-04-18 4,020 +1.01% 11,611

End-of-day quote Korea S.E., April 23, 2024

More quotes
Green Cross Medical Science Corporation is a Korea-based company principally engaged in the medical business. The Company mainly operates its business through three segments: diagnosis reagent segment, blood bag segment and blood dialysate segment. Its diagnosis reagent segment provides in vitro diagnosis reagents and medical equipment. Its blood bag segment provides filter bags and blood bags. The Company distributes its products within domestic market and to overseas markets.
More about the company
  1. Stock Market
  2. Equities
  3. A142280 Stock